NFKB1 and inflammatory bowel disease: Studies have shown that by downregulating the expression of TLR4 and NF-κB, the body’s inflammatory response can be reduced (Ye et al., 2022), and it has a therapeutic effect on inflammatory bowel disease in the mouse model by inhibiting the over-activation of TLR4/NF-κB (Liu et al., 2017).